Back to Authors

Liu, Li

https://orcid.org/0000-0002-1411-5082

Mayo Clinic

Anhui Medical University

Citations 2

Association of Mechanical Circulatory Support With In‐Hospital Outcomes in Non‐Ischemic Cardiogenic Shock: A Nationwide Inpatient Study
Liu, Li , Memon, Burhan, Zou, Tian , Elkhatib, Wiaam , Luo, Pincheng , Billstein, Laura , Kumar, Nomesh , Cheng, Youyou , Fickel, Abigail, Shao, Shengtong, Guglin, Maya, Liu, Li , Billstein, Laura E, Sun, Chenyu , Elkhatib, Wiaam Y , Fickel, Abigail, Shao, Shengtong, Guglin, Maya, Sun, Chenyu

Clinical Cardiology | July 23, 2026 | Volume: 49 | Issue: 7 | Pages: No page available

10.1002/clc.70416 Get It

ABSTRACT Introduction Cardiogenic shock (CS) carries high morbidity and mortality. However, evidence for mechanical circulatory support (MCS) in non‐ischemic CS remains limited, as prior trials have focused on infarct‐related shock. Methods We performed a retrospective cross‐sectional study using the Nationwide Inpatient Sample (2017–2019), identifying hospitalizations with a principal diagnosis of CS and excluding acute myocardial infarction. Patients were categorized into mutually exclusive groups: no MCS, intra‐aortic balloon pump (IABP) only, Impella only, or extracorporeal membrane oxygenation (ECMO) only. Primary outcomes were in‐hospital mortality, length of stay (LOS), and total hospital cost. Survey‐weighted multivariable models adjusted for demographics, hospital characteristics, and comorbidity burden using Elixhauser and Charlson indices. Results Among 104 045 hospitalizations, 6040 received MCS. IABP was most common, followed by Impella and ECMO. Among patients receiving a single MCS strategy, overall in‐hospital mortality was 29.5%., with lower mortality in the IABP group (19.9%) compared with Impella (37.4%) and ECMO (44.3%). After adjustment, IABP was associated with lower observed in‐hospital mortality versus no MCS (aOR 0.58, 95% CI 0.53–0.64; p < 0.01), whereas Impella and ECMO showed increased aOR. IABP and ECMO were associated with longer LOS, while Impella was not. All MCS strategies were associated with higher costs, with ECMO showing the greatest increase (cost ratio 3.30, 95% CI 3.12–3.50). Conclusion In non‐ischemic CS, MCS strategies demonstrate distinct profiles of mortality and resource utilization. IABP was associated with lower observed in‐hospital mortality, whereas all MCS were linked to higher costs, highlighting heterogeneity in outcomes and the need for further research.
Clinical Implications of Subclinical Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Study
Minamisawa, Masatoshi, Claggett, Brian , Čikeš, Maja , Liu, Li , Prasad, Narayana , Biering‐Sørensen, Tor , O’Meara, Eileen , Redfield, Margaret M. , Solomon, Scott D. , Shah, Amil M. , Shah, Amil , Inciardi, Riccardo M. , Lam, Carolyn S.P. , Shah, Sanjiv J , Zile, Michael R. , McMurray, John J.V. , Solomon, Scott David

European Journal of Heart Failure | February 19, 2024 | Volume: 26 | Issue: 4 | Pages: 871-881

10.1002/ejhf.3167 Get It

Abstract Aims Left ventricular (LV) subclinical impairment has been described in heart failure with preserved ejection fraction (HFpEF). We assessed the relationship between LV myocardial deformation by strain imaging and recurrent hospitalization for heart failure (HF) or cardiovascular death in a large international HFpEF population. Methods and results We assessed two-dimensional speckle-tracking based global longitudinal strain (GLS) in 790 patients (mean age 74 ± 8 years, 54% female) with adequate image quality enrolled in the PARAGON-HF echocardiography study. We examined the relationship of GLS with total HF hospitalizations and cardiovascular death (the primary composite outcome) after accounting for clinical confounders. Approximately 47% of the population had evidence of LV subclinical dysfunction, defined as absolute GLS &lt;16%. Impaired GLS was significantly associated with higher values of circulating baseline N-terminal pro-B-type-natriuretic peptide. After a median follow-up of 3.0 years, there were 407 total HF hospitalizations and cardiovascular deaths. After multivariable adjustment, worse GLS was associated with a greater risk for the primary composite outcome (adjusted hazard ratio per 1% decrease: 1.06; 95% confidence interval 1.02–1.11; p = 0.008). GLS did not modify the treatment effect of sacubitril/valsartan compared with valsartan for the composite outcome (p for interaction &gt;0.1). Conclusions In a large HFpEF population, impaired LV function was observed even among patients with preserved ejection fraction, and was associated with an increased risk of total HF hospitalizations or cardiovascular death, accounting for clinical confounders. These findings highlight the key role of subtle LV systolic impairment in the pathophysiology of HFpEF.